

# Ho Kyung Seo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8426477/publications.pdf>

Version: 2024-02-01

67  
papers

888  
citations

759055

12  
h-index

526166

27  
g-index

67  
all docs

67  
docs citations

67  
times ranked

1390  
citing authors

#	ARTICLE	IF	CITATIONS
1	De Ritis Ratio, Neutrophil-to-Lymphocyte Ratio, and Albumin Are Significant Prognostic Factors for Survival Even After Adjusted by the Treatment Duration in Metastatic Kidney and Bladder Cancer Treated With Immune-Checkpoint Inhibitors. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 25-33.	0.1	0
2	Update of the Diagnostic and Therapeutic Role of the Pelvic Lymph Node Dissection Boundaries During Radical Cystectomy in Muscle Invasive Bladder Cancer. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 71-81.	0.1	0
3	Enhanced Recovery After Surgery Program for Radical Cystectomy. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 92-106.	0.1	0
4	Targeted Inhibition of O-Linked $\beta$ -N-Acetylglucosamine Transferase as a Promising Therapeutic Strategy to Restore Chemosensitivity and Attenuate Aggressive Tumor Traits in Chemoresistant Urothelial Carcinoma of the Bladder. <i>Biomedicines</i> , 2022, 10, 1162.	1.4	1
5	Clinical implications and practical considerations for poly-ADP-ribose polymerase inhibitors as a new horizon for the management of urothelial carcinoma of the bladder. <i>Investigative and Clinical Urology</i> , 2022, 63, 369.	1.0	1
6	Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer. <i>Investigative and Clinical Urology</i> , 2021, 62, 361.	1.0	14
7	Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 570077.	1.3	9
8	Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. <i>Lancet Oncology</i> , 2021, 22, 919-930.	5.1	239
9	Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9526.	1.8	8
10	Emerging agents for the treatment of metastatic urothelial cancer. <i>Investigative and Clinical Urology</i> , 2021, 62, 243.	1.0	8
11	A retrospective multicenter comparison of conditional cancer-specific survival between laparoscopic and open radical nephroureterectomy in locally advanced upper tract urothelial carcinoma. <i>PLoS ONE</i> , 2021, 16, e0255965.	1.1	5
12	Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology. <i>Biomedicines</i> , 2021, 9, 1500.	1.4	4
13	Optimizing frontline therapy in advanced urothelial cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 983-985.	0.6	3
14	Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study. <i>Frontiers in Oncology</i> , 2020, 10, 568809.	1.3	3
15	Usefulness of the mass screening program for colorectal cancer in China: further long-term validation is needed to confirm its value. <i>Annals of Translational Medicine</i> , 2020, 8, 427-427.	0.7	0
16	Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1. <i>Prostate</i> , 2020, 80, 453-462.	1.2	12
17	Where are we now and where are we heading in muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 2864-2865.	0.6	3
18	Novel G9a/DNMT first-in-class dual reversible inhibitor has potent antitumor effect in bladder cancer. <i>Translational Cancer Research</i> , 2020, 9, 1319-1321.	0.4	2

#	ARTICLE	IF	CITATIONS
19	Urinary Biomarker in Bladder Cancer at Present Time. <i>The Korean Journal of Urological Oncology</i> , 2020, 18, 183-193.	0.1	0
20	Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study. <i>Investigative and Clinical Urology</i> , 2020, 61, 146.	1.0	0
21	Developing a prediction model for disease-free survival from upper urinary tract urothelial carcinoma in the Korean population. <i>Cancer Medicine</i> , 2019, 8, 4967-4975.	1.3	4
22	Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis. <i>BMC Cancer</i> , 2019, 19, 688.	1.1	5
23	Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study. <i>Investigative and Clinical Urology</i> , 2019, 60, 195.	1.0	5
24	Correlation Analyses of Computed Tomography and Magnetic Resonance Imaging for Calculation of Prostate Volume in Colorectal Cancer Patients with Voiding Problems Who Cannot Have Transrectal Ultrasonography. <i>BioMed Research International</i> , 2019, 2019, 1-8.	0.9	1
25	Single-Center Analysis of Human Papillomavirus Infection and P16INK4A Expression among Korean Patients with Penile Cancer. <i>BioMed Research International</i> , 2019, 2019, 1-7.	0.9	1
26	Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy. <i>PLoS ONE</i> , 2019, 14, e0211105.	1.1	7
27	Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 350-350.	0.8	103
28	Significant clinicopathologic prognostic factors for bladder recurrence, progression, and cancer-specific survival after surgery among patients with upper urinary tract urothelial carcinoma. <i>Investigative and Clinical Urology</i> , 2019, 60, 432.	1.0	6
29	The Comparison of Oncologic Outcomes between Open and Laparoscopic Radical Nephroureterectomy for the Treatment of Upper Tract Urothelial Carcinoma: A Korean Multicenter Collaborative Study. <i>Cancer Research and Treatment</i> , 2019, 51, 240-251.	1.3	14
30	Retrospective Study of the Significant Predictive Role of Inflammatory Degree in Initial and Repeat Prostate Biopsy Specimens for Detecting Prostate Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 910-918.	1.3	2
31	Laparoscopy versus Open Nephroureterectomy in Prognostic Outcome of Patients with Advanced Upper Tract Urothelial Cancer: A Retrospective, Multicenter, Propensity-Score Matching Analysis. <i>Cancer Research and Treatment</i> , 2019, 51, 963-972.	1.3	11
32	Oncologic, Perioperative Outcomes of Female Radical Cystectomy: Results from a Multicenter Study in Korea. <i>Cancer Research and Treatment</i> , 2019, 51, 1064-1072.	1.3	2
33	Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis. <i>Scientific Reports</i> , 2018, 8, 2974.	1.6	4
34	Clear cell papillary renal cell carcinoma: A case report and review of the literature. <i>World Journal of Nephrology</i> , 2018, 7, 155-160.	0.8	1
35	Effect of Neoadjuvant Hormone Therapy on Resection Margin and Survival Prognoses in Locally Advanced Prostate Cancer after Prostatectomy Using Propensity-Score Matching. <i>BioMed Research International</i> , 2018, 2018, 1-7.	0.9	9
36	A Surgically Treated Case of Ureterovesical Amyloidosis of the Bladder in a Patient with Idiopathic Thrombocytopenia. <i>Case Reports in Urology</i> , 2018, 2018, 1-4.	0.1	2

#	ARTICLE	IF	CITATIONS
37	Immune checkpoint inhibitors for urothelial carcinoma. <i>Investigative and Clinical Urology</i> , 2018, 59, 285.	1.0	94
38	Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. , 2018, , 337-352.		0
39	The neutrophil-to-lymphocyte ratio makes the Heng risk model improve better the prediction of overall survival in metastatic renal cell cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 835-840.	0.6	8
40	Prostate stem cell antigen mRNA in blood is a predictor of survival after radical prostatectomy in patients with high-risk prostate cancer. <i>Oncotarget</i> , 2018, 9, 26291-26298.	0.8	3
41	Evaluation of the Efficacy of Solifenacin for Preventing Catheter-Related Bladder Discomfort After Transurethral Resection of Bladder Tumors in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective, Randomized, Multicenter Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 157-162.	0.9	11
42	Pretreatment Prognostic Nutritional Index Is an Independent Predictor of Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Targeted Therapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 100-111.	0.9	28
43	Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine. <i>BioMed Research International</i> , 2017, 2017, 1-9.	0.9	6
44	Prostate Cancer in a Patient with a Family History of BRCA Mutation: a Case Report and Literature Review. <i>Journal of Korean Medical Science</i> , 2017, 32, 377.	1.1	11
45	A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy. <i>Oncotarget</i> , 2017, 8, 93633-93643.	0.8	13
46	Recommended oral sodium bicarbonate administration for urine alkalinization did not affect the concentration of mitomycin-C in non-muscle invasive bladder cancer patients. <i>Oncotarget</i> , 2017, 8, 96117-96125.	0.8	3
47	Initial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naïve, unresectable metastatic renal cell carcinoma. <i>PLoS ONE</i> , 2017, 12, e0177975.	1.1	2
48	The Retrospective Analysis of Prognostic Significance of Smoking Status in Bladder Cancer. <i>The Korean Journal of Urological Oncology</i> , 2017, 15, 111-120.	0.1	0
49	Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy. <i>PLoS ONE</i> , 2016, 11, e0151646.	1.1	5
50	A Case Report of Partial Nephrectomy of Mucinous Cystadenocarcinoma in Kidney and Its Literature Review. <i>Cancer Research and Treatment</i> , 2016, 48, 838-842.	1.3	4
51	Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy. <i>Cancer Research and Treatment</i> , 2016, 48, 1092-1101.	1.3	24
52	P70S6K and Elf4E Dual Inhibition Is Essential to Control Bladder Tumor Growth and Progression in Orthotopic Mouse Non-muscle Invasive Bladder Tumor Model. <i>Journal of Korean Medical Science</i> , 2015, 30, 308.	1.1	6
53	Trends in the Use of Chemotherapy before and after Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer in Korea. <i>Journal of Korean Medical Science</i> , 2015, 30, 1150.	1.1	20
54	Outcomes of pelvic exenteration for recurrent or primary locally advanced colorectal cancer. <i>Annals of Surgical Treatment and Research</i> , 2015, 89, 131.	0.4	13

#	ARTICLE	IF	CITATIONS
55	Oncologic aspects of long-term followed incidental prostate cancer detected by cystoprostatectomy in Korean patients. <i>Prostate International</i> , 2015, 3, 56-61.	1.2	6
56	The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer. <i>BMC Urology</i> , 2015, 15, 82.	0.6	7
57	Establishment of an Orthotopic Mouse Non-Muscle Invasive Bladder Cancer Model Expressing the Mammalian Target of Rapamycin Signaling Pathway. <i>Journal of Korean Medical Science</i> , 2014, 29, 343.	1.1	3
58	Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib. <i>Annals of Surgical Oncology</i> , 2013, 20, 4397-4404.	0.7	34
59	Genetic Variations of <i>±</i> -Methylacyl-CoA Racemase Are Associated with Sporadic Prostate Cancer Risk in Ethnically Homogenous Koreans. <i>BioMed Research International</i> , 2013, 2013, 1-11.	0.9	4
60	Prostate Volume has Prognostic Value Only in Pathologic T2 Radical Prostatectomy Specimens. <i>Journal of Korean Medical Science</i> , 2011, 26, 807.	1.1	13
61	Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer. <i>Journal of Surgical Oncology</i> , 2010, 101, 145-148.	0.8	26
62	Prostate Specific Membrane Antigen mRNA in Blood as a Potential Predictor of Biochemical Recurrence after Radical Prostatectomy. <i>Journal of Korean Medical Science</i> , 2010, 25, 1291.	1.1	8
63	Identification of Immunohistochemical Factors That Predict the Synchronous or Metachronous Development of Bladder Tumors in Patients with Upper Urinary Tract Tumors. <i>Urologia Internationalis</i> , 2008, 81, 306-311.	0.6	23
64	Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer : Comparative Analysis between 1st-line and 2nd-line Docetaxel. <i>Yonsei Medical Journal</i> , 2008, 49, 775.	0.9	9
65	Single Institutional Experience of Bladder-Preserving Trimodality Treatment for Muscle-Invasive Bladder Cancer. <i>Journal of Korean Medical Science</i> , 2008, 23, 598.	1.1	6
66	Adult's Wilms' Tumor Mimicking Renal Pelvis Tumor. <i>Korean Journal of Urology</i> , 2007, 48, 558.	0.2	0
67	Analysis of Changes in the Total Lymphocyte and Eosinophil Count during Immunotherapy for Metastatic Renal Cell Carcinoma: Correlation with Response and Survival. <i>Journal of Korean Medical Science</i> , 2007, 22, S122.	1.1	9